R. A. Robins

Capture of recombinant ricin A chain by a bispecific anti-RTA: anti-CEA monoclonal antibody pre-targeted to a human gastric carcinoma xenograft in nude mice

SummaryA bispecific antibody against carcinoembryonic antigen (CEA) and ricin A chain has been shown to localise in a CEA-producing human tumour xenograft. When labelled recombinant ricin A chain was subsequently injected there was uptake into tumours, indicating that this bispecific antibody can capture or carry toxin into tumour deposits.

Monoclonal Antibodies to a Tumor Specific Antigen on Rat Mammary Carcinoma Sp4 and Their Use in Drug Delivery Systems

With the development of techniques for producing monoclonal antibodies to cell surface antigens, the identification and typing of tumor-associated antigens is entering a new and sophisticated phase (Baldwin et al, 1981). There are, for example, a range of monoclonal antibodies which react with antigens associated exclusively, or more frequently at greatly increased levels, on human tumors including malignant melanoma, osteogenic sarcoma, neuroblastoma and colon carcinoma (see chapters 9–11, this volume). These monoclonal antibodies may have several applications in addition to their use for isolating and identifying tumor-associated antigens. This includes the use of radioisotopically labelled antibodies for identification of tumor deposits by Y-scintigraphy. Additionally monoclonal antibodies may be used as carriers for anti-tumor agents, thus providing an approach for selective attack upon malignant cells. There are several options available in the choice of anti-tumor agents but currently, attention is being given to plant and bacterial toxins, cytotoxic drugs and biological response modifiers including interferon (Baldwin et al, 1981: Baldwin and Byers, 1982).

Diagnostic and Therapeutic Applications of a Monoclonal Antibody Against Human Osteogenic Sarcoma

Abstract A murine monoclonal antibody (791T/36) which reacts with antigens expressed upon human osteogenic sarcoma cells has been evaluated for detecting human tumour xenografts by external imaging techniques. 131I-labelled antibody imaged tumours when used in conjunction with 113mIn for blood pool labelling and a computerized subtraction technique for image enhancement. This monoclonal antibody has also been evaluated as a reagent for targetting anti-tumour agents. This is illustrated by studies in which antibody conjugated to interferon has been used to bind interferon to tumour cells for the local activation of natural killer cells